$OPK Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency.. https://t.co/XwiU6nCbGo
@MightySoldiers @TrendSpider 

#stockmarket #stocks #charts 

https://t.co/qrK839n5GY